ImmunityBio, Inc. (NASDAQ:IBRX - Get Free Report) shares dropped 8.1% during mid-day trading on Friday . The stock traded as low as $5.54 and last traded at $5.57. Approximately 1,386,989 shares changed hands during trading, a decline of 65% from the average daily volume of 3,955,388 shares. The stock had previously closed at $6.06.
Wall Street Analysts Forecast Growth
Separately, Piper Sandler boosted their price target on shares of ImmunityBio from $4.00 to $5.00 and gave the company a "neutral" rating in a research report on Monday, March 25th.
Get Our Latest Report on IBRX
ImmunityBio Stock Performance
The firm's 50-day moving average price is $5.06 and its two-hundred day moving average price is $3.90. The stock has a market cap of $3.46 billion, a price-to-earnings ratio of -4.79 and a beta of 1.23.
ImmunityBio (NASDAQ:IBRX - Get Free Report) last announced its quarterly earnings results on Tuesday, March 19th. The company reported ($0.19) earnings per share for the quarter, missing the consensus estimate of ($0.18) by ($0.01). The firm had revenue of $0.14 million for the quarter, compared to analysts' expectations of $0.03 million. As a group, sell-side analysts expect that ImmunityBio, Inc. will post -0.68 earnings per share for the current fiscal year.
Institutional Inflows and Outflows
A number of large investors have recently bought and sold shares of the stock. Armistice Capital LLC purchased a new stake in ImmunityBio during the first quarter worth about $10,549,000. State Street Corp increased its stake in ImmunityBio by 255.9% during the third quarter. State Street Corp now owns 6,649,331 shares of the company's stock worth $33,047,000 after purchasing an additional 4,780,807 shares during the period. Vanguard Group Inc. increased its stake in ImmunityBio by 42.0% during the third quarter. Vanguard Group Inc. now owns 14,675,687 shares of the company's stock worth $24,802,000 after purchasing an additional 4,342,386 shares during the period. BlackRock Inc. increased its stake in ImmunityBio by 36.4% during the second quarter. BlackRock Inc. now owns 9,498,666 shares of the company's stock worth $26,406,000 after purchasing an additional 2,533,147 shares during the period. Finally, Geode Capital Management LLC increased its stake in ImmunityBio by 40.3% during the second quarter. Geode Capital Management LLC now owns 2,730,452 shares of the company's stock worth $7,591,000 after purchasing an additional 784,588 shares during the period. Institutional investors and hedge funds own 8.58% of the company's stock.
ImmunityBio Company Profile
(
Get Free Report)
ImmunityBio, Inc, a clinical-stage biotechnology company, engages in discovering, developing, and commercializing next-generation immuno- and cellular therapies for cancer and infectious diseases in the United States and Europe. The company offers immunotherapy and cell therapy platforms, including antibody cytokine fusion protein N-803, vaccine delivery technologies, and natural killer cell therapies.
Further Reading
Before you consider ImmunityBio, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and ImmunityBio wasn't on the list.
While ImmunityBio currently has a "Hold" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Click the link below and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising.
Get This Free Report
